News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Information on the Annual General Meeting and Covid-19

April 2, 2020

PledPharma AB (STO: PLED) has decided to take a number of preventive measures before the annual general meeting to minimize the risk of spreading the new corona virus Covid-19.

The goal for the AGM is to be short and efficient with the least risk of spreading the infection. This can for example result in shortened introduction and presentations. Coffee and sweets will neither be served in conjunction with the AGM.
PledPharma reminds shareholders about the possibility of not attending the AGM in person. Shareholders can instead use the possibility of voting through a proxy. Shareholders that are ill, have symptoms of the disease, been visiting infectious disease risk areas or belong to a risk group should participate through a proxy. A proxy form for representatives is available on the Company's website www.pledpharma.se.
PledPharma closely monitors the development of the spread of infection and the authorities' directives and publishes updated information on the company's website www.pledpharma.se if necessary.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com